Sepsis trials. Intersection of investigation, regulation, funding, and practice.
Bernard
G R
GR
Division of Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.
D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004731:Endotoxins / Q000037:antagonists & inhibitors; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D008775:Methylprednisolone / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D012107:Research Design; D012109:Research Support as Topic; D012795:Sialoglycoproteins / Q000627:therapeutic use; D018746:Systemic Inflammatory Response Syndrome / Q000276:immunology / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D016861:Cyclooxygenase Inhibitors; D004731:Endotoxins; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D017472:Receptors, Interleukin-1; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha; D008775:Methylprednisolone